Results: 6

Community knowledge and practices regarding antibiotic use in rural Mozambique: where is the starting point for prevention of antibiotic resistance?

BMC public health (Online); 20 (1183), 2020
Background: Antibiotic misuse and other types of unnecessary use of antibiotics can contribute to accelerate the process of antibiotic resistance, which is considered a global concern, mostly affecting low-and middle-income countries (LMICs). In Mozambique there is limited evidence on community knowledge...

Performance characteristics of finger-stick dried blood spots (DBS) on the determination of human immunodeficiency virus (HIV) treatment failure in a pediatric population in Mozambique

PLos ONE; 12 (7), 2017
Quantitative plasma viral load (VL) at 1000 copies /mL was recommended as the threshold to confirm antiretroviral therapy (ART) failure by the World Health Organization (WHO). Because of ongoing challenges of using plasma for VL testing in resource-limited settings (RLS), especially for children, this st...

Determinants of virological failure and antiretroviral drug resistance in Mozambique

J. antimicrob. chemother; 70 (9), 2015
Objectives: The objective of this study was to inform public health actions to limit first-line ART failure and HIV drug resistance in Mozambique. Methods: This was a cross-sectional study. HIV-1-infected adults on first-line ART for at least 1 year attending routine visits in the Manhiça District Hospi...

Trends in Prevalence of HIV-1 Drug Resistance in a Public Clinic in Maputo, Mozambique

PLos ONE; 10 (7), 2015
Background: An observational study was conducted in Maputo, Mozambique, to investigate trends in prevalence of HIV drug resistance (HIVDR) in antiretroviral (ART) naïve subjects initiating highly active antiretroviral treatment (HAART). Methodology/principal findings: To evaluate the pattern of drug res...

Genetic analysis and natural polymorphisms in HIV-1 gp41 isolates from Maputo City, Mozambique

AIDS res. hum. retrovir; 30 (6), 2014
Enfuvirtide was the first fusion inhibitor approved by the Food and Drug Administration (FDA) in 2003 for HIV-1 infection in treatment-experienced patient. It is the first approved antiviral agent to attack the HIV life cycle in its early stages. For HIV fusion to occur, the HR1 and HR2 domains in the gp...

Risk of extended viral resistance in human immunodeficiency virus-1-infected Mozambican children after first-line treatment failure

Pediatr. infect. dis. j; 28 (12), 2009
Background: Resistant virus may be selected by sub-optimal control of HIV-1 replication during antiretroviral treatment. The incidence and profile of resistance in children receiving World Health Organization-recommended treatment remains to be evaluated on a large scale. Goals: Assessment of the frequen...